the aid library

LIST OPTIONS

Filter

9579

Transporting, Storing, and Handling Malaria Rapid Diagnostic Tests at Central and Peripheral Storage Facilities

USAID Deliver Project (2009) C2

In most malaria-endemic countries, temperatures frequently exceed the recommended storage temperatures for malaria RDTs. Correct storage of the RDTs may be difficult, especially during transport and in locations where air-conditioning is unavailable. This publication is intended to support health p... more

Download (190)

View PDF (186)

Air pollution and the noncommunicable disease prevention agenda: opportunities for public health and environmental science

Howse, E.; Crane, M.; Hanigan, I. et al. Environmental Research Letters (2021) CC

Air pollution is a major environmental risk factor and contributor to chronic, noncommunicable diseases (NCDs). However, most public health approaches to NCD prevention focus on behavioural and biomedical risk factors, rather than environmental risk factors such as air pollution. This article discus... more

Download (197)

View PDF (464)

Operational considerations for managing COVID-19 cases/outbreak on board ships

World Health Organization WHO (2020) C1

This document has been prepared based on the evidence currently available about Coronavirus disease 2019 (COVID-19) transmission (human-to-human transmission via respiratory droplets or direct contact from an infected individual). It is recommended to use it in conjunction with the published World... more

Download (286)

View PDF (242)

Ghana Annual Report 2019

World Health Organization WHO; Regional Office for Africa (2020) C_WHO

The WHO country office for Ghana, began the year 2019 with a 4-day staff retreat at the Busua Beach Resort in the Western Region from 04 to 08 March 2019. The theme for the retreat was ‘Impacting the Health and Lives of the people of Ghana through the Triple Billion Goal”. The staff outlined pri... more

Download (332)

View PDF (324)

Mpox Strategic Preparedness, Readiness, and Response Plan: Global Monitoring and Evaluation Framework

World Health Organization WHO Reliefweb OCHA Services (2022) C_WHO

This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts and WHO support to Member States. Regular collection and analysis of da... more

Download (307)

View PDF (470)

Breathe - Let’s end TB and AIDS by 2030

UNAIDS (2018) C1

“It has never been more urgent for us to come together to end HIV and tuberculosis. We achieve the most when we work together, using all of our strengths, harnessing all of our collective potential to end HIV and tuberculosis for a healthier world as part of the Sustainable Development Goals.” �... more

External Link

Nature-Based Solutions and Protected Areas to Improve Urban Biodiversity and Health

MacKinnon,K.; van Ham, C.; Reilly, K.; et al. Springer International Publishing (2019) CC

Biodiversity and healthy natural ecosystems, including protected areas in and around cities, provide ecosystem benefits and services that support human health, including reducing flood risk, filtering air pollutants, and providing a reliable supply of clean drinking water. These services help to red... more

Download (305)

View PDF (313)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Download (910)

View PDF (1044)

Patents and licences on antiretrovirals: A snapshot

UNITAID; WHO (2014)

The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ... more

External Link

COVID-19: Occupational health and safety for health workers
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance 2 February 2021 . Available in Arabic, Chinese, English, French, Ukranian, Russian Health workers are at the front line of the COVID-19 outbreak response and as such are exposed to different hazards that put them at risk. Occupational hazards include exposure to SARS-CoV-2 and othe... more

External Link

Antimicrobial Resistance Global Report on Surveillance
recommended

World Health Organization (WHO) (2014) C_WHO

The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para... more

Download (437)

View PDF (660)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (518)

View PDF (1069)

Mental Health Atlas 2020
recommended

World Health Organization (WHO) (2021) C_WHO

The Mental Health Atlas, released every three years, is a compilation of data provided by countries around the world on mental health policies, legislation, financing, human resources, availability and utilization of services and data collection systems. It serves as a guide for countries for the de... more

External Link

Code Red for Health response in Latin America and the Caribbean: Enhancing peoples' health through climate action

Yglesias_González; M.; et al. (2022) CC

The Lancet Regional Health - Americas 2022;00: 100248 Published online xxx https://doi.org/10.1016/j.lana.2022.100248. The Lancet Countdown report, discuss the overlapping social, climate and health challenges in Latin America and the Caribbean, and urge multisectoral and political action to trans... more

External Link

MSF Essential Drugs - Practical Guidelines 2022
recommended

Médecins sans Frontières MSF Médecins sans Frontières (2022) C2

Practical guide intended for physicians, pharmacists, nurses and medical auxiliaries. This guide is not a dictionary of pharmacological agents. It is a practical manual intended for health professionals, physicians, pharmacists, nurses and health auxiliaries invoved in curative care and drug managem... more

Download (1110)

View PDF (1312)

A framework for malaria elimination

World Health Organization WHO (2017) C_WHO

The document provides guidance on the tools, activities and strategies required to achieve malaria elimination and prevent re-establishment of transmission in countries, regardless of where they lie across the spectrum of transmission intensity. It is intended to inform national malaria elimination ... more

Download (2332)

View PDF (2619)

WHO Monographs On Selected Medicinal Plants - Volume 3

World Health Organization WHO (2007) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (294)

View PDF (428)

Family planning and comprehensive abortion care toolkit for the primary health care workforce: volume 1

World Health Organisation (WHO) (2022) C_WHO

What are the FP and CAC competencies? Through the clear articulation of the family planning and comprehensive abortion care (FP and CAC) competencies for the primary health care workforce, the aim is to advance improvements in FP and CAC service delivery by aligning health worker education approach... more

Download (380)

View PDF (604)

Lao PDR: Disaster Management Reference Handbook

Center for Excellence in Disaster Management and Humanitarian Assistance (2017) C1

Lao People’s Democratic Republic (Lao PDR), also referred to as Laos, or Lao, is exposed to natural disasters such as flooding, typhoons, cyclones, drought, and earthquakes. The country is vulnerable to recurrent, sudden-onset and slow onset natural disasters with flooding, storms and typhoons hav... more

Download (1792)

View PDF (2251)

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers

World Health Organization WHO (2021) C_WHO

2nd. edition The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ... more

COVID-19: Occupational health and safety for health workers recommended

Antimicrobial Resistance Global Report on Surveillance recommended

Mental Health Atlas 2020 recommended

MSF Essential Drugs - Practical Guidelines 2022 recommended

COVID-19: Occupational health and safety for health workers
recommended

Antimicrobial Resistance Global Report on Surveillance
recommended

Mental Health Atlas 2020
recommended

MSF Essential Drugs - Practical Guidelines 2022
recommended